Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Completed · Phase 3

Conditions studied: Acquired Immunodeficiency Syndrome, HIV Infections

In brief

This study will evaluate the non-inferiority of Stribild® (elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF)) single-tablet regimen (STR) relative to regimens consisting of a protease inhibitor (PI) boosted with ritonavir (RTV) plus Truvada® (FTC/TDF) fixed-dose combination in maintaining HIV-1 RNA \< 50 copies/mL at Week 48 in virologically suppressed, HIV-1 infected adults. This study will also evaluate the safety, tolerability, and efficacy of the two regimens through 96 weeks of treatment.

Key facts

Study ID: NCT01475838
Run by: Gilead Sciences
People needed: 438
Starts: 2011-11-01
Expected to finish: 2014-12-01
Last updated by the study team: 2016-06-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Ability to understand and sign a written informed consent form
Be on a stable antiretroviral regimen consisting of a ritonavir boosted PI plus FTC/TDF continuously for ≥ 6 consecutive months preceding the screening visit
Be on the first or second antiretroviral drug regimen documented undetectable plasma HIV 1 RNA levels for ≥ 6 months preceding the screening visit
No previous use of any approved or experimental integrase strand transfer inhibitor (INSTI) for any length of time
Documented historical genotype prior to starting initial antiretroviral therapy showing no known resistance to TDF or FTC
HIV RNA < 50 copies/mL at screening
Normal ECG
Hepatic transaminases ≤ 5 × the upper limit of the normal range (ULN)
Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin
Adequate hematologic function
Serum amylase ≤ 5 × ULN
Estimated glomerular filtration rate ≥ 70 mL/min
Females of childbearing potential must agree to utilize highly effective contraception methods, or be nonheterosexually active, practice sexual abstinence from screening throughout the duration of the study period and for 30 days following the last dose of study drug
Female participants who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing
Male participants must agree to utilize a highly effective method of contraception during heterosexual intercourse from the screening visit, throughout the duration of the study and for 30 days following discontinuation of investigational medicinal product, or must be nonheterosexually active, or practice sexual abstinence
Age ≥ 18 years

You may not qualify if…

A new AIDS-defining condition diagnosed within the 30 days prior to screening
Females who are breastfeeding
Positive serum pregnancy test (female of childbearing potential)
Receiving drug treatment for hepatitis C, or participants who are anticipated to receive treatment for hepatitis C during the course of the study
Experiencing decompensated cirrhosis
Have an implanted defibrillator or pacemaker
Current alcohol or substance abuse that would interfere with compliance
A history of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous squamous carcinoma
Active, serious infections requiring parenteral antibiotic or antifungal therapy within 30 days prior to Baseline, except for intramuscular penicillin for the treatment of syphilis
Have been treated with immunosuppressant therapies or chemotherapeutic agents within 3 months of study screening, or expected to receive these agents or systemic steroids during the study
Receiving ongoing therapy with any of the medications, including drugs not to be used with elvitegravir, cobicistat, FTC, or TDF; or those with any known allergies to the excipients of E/C/F/TDF tablets, or FTC/TDF tablets
No anticipated need to initiate drugs during the study that are contraindicated
Receiving other investigational drugs
Participation in any other clinical trial
Any other clinical condition or prior therapy that would make the participant unsuitable for the study or unable to comply with the dosing requirements

Where it is running

Pueblo Family Physicians — Phoenix, Arizona, United States
AIDS Healthcare Foundation — Beverly Hills, California, United States
Pacific Oaks Medical Group — Beverly Hills, California, United States
Kaiser Permanente — Hayward, California, United States
Kaiser Permanente — Los Angeles, California, United States
Peter J. Ruane, M.D., Inc. — Los Angeles, California, United States
OASIS Clinic — Los Angeles, California, United States
Anthony Mills MD Inc — Los Angeles, California, United States
Stanford University — Palo Alto, California, United States
University of California, Davis — Sacramento, California, United States
Kaiser Permanente — Sacramento, California, United States
La Playa Medical Group and Clinical Research — San Diego, California, United States
Metropolis Medical — San Francisco, California, United States
Kaiser Permanente San Francisco — San Francisco, California, United States
Dupont Circle Physicians Group, P.C — Washington D.C., District of Columbia, United States
Capital Medical Associates, PC — Washington D.C., District of Columbia, United States
Gary Richmond, MD — Fort Lauderdale, Florida, United States
Midway Immunology & Research Center, LLC — Ft. Pierce, Florida, United States
The Kinder Medical Group — Miami, Florida, United States
Orlando Immunology Center — Orlando, Florida, United States
Idocf/Valuhealthmd, Llc — Orlando, Florida, United States
Infectious Diseases Associates of NW FL, P.A. — Pensacola, Florida, United States
AHF Health Positive Tampa Bay — Safety Harbor, Florida, United States
St. Joseph's Comprehensive Research Institute — Tampa, Florida, United States
Spectrum Medical Group — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.